Targeted inhibition of Akt, which may downregulate ACE2 expression in COVID‐19 and may increase Tregs, inhibits excessive inflammation, CS, pulmonary fibrosis, and platelet activation associated with advanced COVID‐19.298. This evidence concerns the gene AKT1 and Cowden syndrome 1.